1
|
Fuchs L, Wilf-Yarkoni A, Kolb H, Vigiser I, Regev K, Zur D, Habot-Wilner Z, Oron Y, Furer V, Shimon N, Hellmann MA, Lotan I, Auriel E, Rennebohm R, Elkayam O, Karni A. Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study. NEUROLOGY(R) NEUROIMMUNOLOGY & NEUROINFLAMMATION 2025; 12:e200357. [PMID: 39693597 DOI: 10.1212/nxi.0000000000200357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2024] [Accepted: 11/05/2024] [Indexed: 12/20/2024]
Abstract
BACKGROUND AND OBJECTIVES Susac syndrome (SuS) is a rare disorder characterized by encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss, often accompanied by vertigo. Recent updates to diagnostic criteria and treatment guidelines have been made. This study examines clinical manifestations; disease activity; and risk factors of disability, dependency, and return to work in patients with SuS. METHODS A retrospective multicenter study was conducted on 20 consecutive patients with SuS with at least 2 years of follow-up. Clinical and paraclinical activities were assessed and rated according to the severity at onset and the end of follow-up. Cognitive function was assessed using the Montreal Cognitive Assessment while disability and dependence in daily activities were measured using the modified Rankin Scale. Employment status was graded. RESULTS The mean age at onset was 38.9 years, with a mean follow-up of 55.9 months. The female-to-male ratio was 1.86, and 45% of patients had the complete clinical triad. Severe cerebral involvement at onset was associated with a higher risk of cerebral exacerbations within the first year and with an increased long-term disability and dependency. Cognitive function improved in 75% of patients during follow-up. At disease onset, hearing loss excluding low frequencies occurred in 46.7%. Relapse of hearing loss was associated with greater impairment in daily activities. Male sex and elevated CSF protein levels were linked to poorer prognosis. Cerebral and inner ear exacerbations were most common in the first year while retinal exacerbations occurred more frequently, mainly within the first 2 years. Approximately 50% of patients resumed employment while 25% did not return to work. DISCUSSION Current treatment strategies for SuS do not fully prevent relapses. Severe brain manifestation at onset, male sex, and high CSF protein levels are risk factors of a worse prognosis of disability and dependence, indicating the need for intensive treatment. High-frequency hearing loss does not exclude SuS diagnosis.
Collapse
Affiliation(s)
- Lior Fuchs
- The Faculty of Medical & Health Sciences, Tel Aviv University
| | - Adi Wilf-Yarkoni
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Neurology, Rabin Medical Center, Petach Tiqva
| | - Hadar Kolb
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Neuroimmunology and MS Unit, Neurology Institute, Tel Aviv Sourasky Medical Center
| | - Ifat Vigiser
- Neuroimmunology and MS Unit, Neurology Institute, Tel Aviv Sourasky Medical Center
| | - Keren Regev
- Neuroimmunology and MS Unit, Neurology Institute, Tel Aviv Sourasky Medical Center
| | - Dinah Zur
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Division of Ophthalmology, Tel Aviv Sourasky Medical Center
| | - Zohar Habot-Wilner
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Division of Ophthalmology, Tel Aviv Sourasky Medical Center
| | - Yahav Oron
- Department of Otolaryngology, Head, Neck and Maxillofacial Surgery, Tel Aviv Sourasky Medical Center
| | - Viktoria Furer
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Rheumatology, Tel Aviv Sourasky Medical Center
| | - Nitai Shimon
- Department of Neurology, Shamir Medical Center, Rishon le'Zion, Israel
| | - Mark A Hellmann
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Neurology, Rabin Medical Center, Petach Tiqva
| | - Itay Lotan
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Neurology, Rabin Medical Center, Petach Tiqva
| | - Eitan Auriel
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Neurology, Rabin Medical Center, Petach Tiqva
| | - Robert Rennebohm
- The Susac Syndrome Consultation Service and Department of Pediatric Rheumatology, Cleveland Clinic, OH; and
| | - Ori Elkayam
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Department of Rheumatology, Tel Aviv Sourasky Medical Center
| | - Arnon Karni
- The Faculty of Medical & Health Sciences, Tel Aviv University
- Neuroimmunology and MS Unit, Neurology Institute, Tel Aviv Sourasky Medical Center
- Sagol School of Neuroscience, Tel Aviv University, Israel
| |
Collapse
|
2
|
Piura Y, Bregman N, Kavé G, Karni A, Kolb H, Vigiser I, Day GS, Lopez-Chiriboga S, Shiner T, Regev K. Long-term cognitive outcomes in Susac syndrome: A case series. J Neuroimmunol 2024; 393:578396. [PMID: 38908330 DOI: 10.1016/j.jneuroim.2024.578396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 05/17/2024] [Accepted: 06/19/2024] [Indexed: 06/24/2024]
Abstract
Susac syndrome (SuS) presents with encephalopathy, visual disturbances, and hearing loss from immune-mediated microvascular occlusion. While acute SuS is well-described, long-term cognitive outcomes with current treatments are underknown. We assessed ten SuS patients treated in accordance with evidence-based guidelines using immunotherapies targeting humoral and cell-mediated pathways. Patients were followed for a median 3.6 years. Initially, cognition inversely correlated with corpus callosum lesions on MRI. All reported cognitive improvement; 5/10 patients had residual deficits in visual attention and executive function. Early, aggressive treatment was associated with good outcomes; extensive early corpus callosum lesions may identify patients at-risk of persistent cognitive deficits.
Collapse
Affiliation(s)
- Yoav Piura
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; The Neuroimmunology and Multiple Sclerosis Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
| | - Noa Bregman
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel; Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Gitit Kavé
- Department of Education and Psychology, The Open University of Israel, Ra'anana, Israel; Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Arnon Karni
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; The Neuroimmunology and Multiple Sclerosis Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Hadar Kolb
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; The Neuroimmunology and Multiple Sclerosis Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Ifat Vigiser
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel; The Neuroimmunology and Multiple Sclerosis Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Gregory S Day
- Department of Neurology, Mayo Clinic in Florida, Jacksonville, FL, USA
| | | | - Tamara Shiner
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel; Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; Cognitive Neurology Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| | - Keren Regev
- Department of Neurology, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel; The Neuroimmunology and Multiple Sclerosis Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel
| |
Collapse
|
3
|
Kim S, Shin HY. Susac Syndrome With Good Response to Intravenous Immunoglobulin: A Case Report. J Clin Neurol 2023; 19:506-508. [PMID: 37635430 PMCID: PMC10471543 DOI: 10.3988/jcn.2023.0025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 04/19/2023] [Accepted: 05/08/2023] [Indexed: 08/29/2023] Open
Affiliation(s)
- Seokhyun Kim
- Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, Korea
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Ha Young Shin
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
| |
Collapse
|
4
|
Abstract
PURPOSE To evaluate the effect of tumor necrosis factor (TNF) inhibitor therapy on ocular relapses in patients with Susac syndrome. METHODS Multicenter retrospective cohort study of patients diagnosed with Susac syndrome according to classical clinical criteria. We evaluated the disease activity before and after introduction of anti-TNF therapy and its value as a steroid-sparing agent. RESULTS Five patients were included. All were initially treated with a combination of corticosteroids and classical immunosuppressive drugs. Infliximab was started in three patients, and adalimumab was started in two patients. Patients had on average 5 ocular relapses during a mean follow-up time of 2.59 years before introducing a TNF inhibitor, corresponding with on average 1.93 relapses per year. After the introduction of an anti-TNF agent, this number was reduced by factor 5.51 to an average of 0.35 relapses per year for a mean follow-up of 2.86 years (P = 0.10). Before anti-TNF introduction ocular relapses occurred at a mean daily dose of 34 mg of prednisone, whereas with anti-TNF treatment, corticosteroid administration could be completely stopped in four patients with one patient still needing 5 mg daily (P = 0.10). Infliximab and adalimumab generally were well tolerated, and no serious adverse events were reported. CONCLUSION Although not statistically significant, our results suggest that anti-TNF therapy can be a valuable option for the treatment of ocular Susac syndrome and may especially be considered in those patients unresponsive to more conventional immunosuppressive treatment.
Collapse
|
5
|
Willekens B, Kleffner I. Susac syndrome and pregnancy: a review of published cases and considerations for patient management. Ther Adv Neurol Disord 2021; 14:1756286420981352. [PMID: 33796140 PMCID: PMC7970706 DOI: 10.1177/1756286420981352] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Accepted: 11/24/2020] [Indexed: 12/31/2022] Open
Abstract
Susac syndrome (SuS) is a rare autoimmune endotheliopathy leading to hearing loss, branch retinal artery occlusions and encephalopathy. Young females are more frequently affected than males, making counselling for family planning an important issue. We reviewed published cases on SuS during pregnancy or in the postpartum period, and selected 27 reports describing the details of 33 patients with SuS. Treatment options and implications for pregnancy and breastfeeding are discussed. We propose new areas for research and suggest a management strategy.
Collapse
Affiliation(s)
- Barbara Willekens
- Department of Neurology, Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
| | - Ilka Kleffner
- University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany
| |
Collapse
|
6
|
Abstract
BACKGROUND Susac syndrome (SS) classically presents with the clinical triad of retinal artery occlusion, sensorineural hearing loss, and encephalopathy and the neuroimaging triad of white matter lesions, deep gray matter lesions, and leptomeningeal disease. However, patients can present with an incomplete clinical or neuroimaging triads making diagnosis difficult in certain situations. A standard treatment paradigm also is lacking in this illness. It is important for neuro-ophthalmologists to recognize clinical and radiographic findings that are pathognomonic for this syndrome and have a basic understanding of the available treatment options. EVIDENCE ACQUISITION Review of medical literature. RESULTS A definite diagnosis of SS is made when the clinical triad or the neuroimaging triad is present. There are numerous reports of 2 other imaging findings in this condition: arteriolar wall hyperfluorescence (AWH) on fluorescein angiography in retinal arterioles remote from retinal ischemia and central callosal lesions on MRI. Both of these imaging findings are diagnostic of SS. Gass plaques in retinal arterioles are almost always seen in the acute phase of the illness but are not pathognomonic for SS. The most common medications used in this syndrome are corticosteroids and intravenous immunoglobulin. A number of other medications have been used including mycopheolate, rituximab, azathioprine, and cyclophosphamide. CONCLUSIONS In the absence of the clinical triad or magnetic resonance imaging triad for SS, AWH remote from retinal vascular injury and central callosal lesions are confirmatory of the diagnosis because they have never been described in any other condition. The presence of Gass plaques in retinal arterioles should strongly suggest the diagnosis. Despite the lack of clinical trial data, patients with SS must be treated promptly and aggressively. In more fulminant cases, addition of mycophenolate mofetil or rituximab is required, followed by cyclophosphamide when disease is refractory to other medications.
Collapse
|
7
|
Ramos-Ruperto L, Martínez-Sánchez N, Bartha-Rasero JL, Robles-Marhuenda Á. Susac syndrome and pregnancy: a relationship to clarify. About two cases and review of the literature. J Matern Fetal Neonatal Med 2020; 35:181-186. [PMID: 31937158 DOI: 10.1080/14767058.2020.1712712] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Background: Susac syndrome is a vasculopathy that affects the central nervous system, mainly the brain parenchyma, retina and inner ear. It affects mainly young women and. Management is based on expert consensus and in pregnant women the treatment is not well established. It is necessary to start treatment early because of its potential severity and sequelae.Method: We present two cases of Susac syndrome related to pregnancy/puerperium and performed a review of the literature.Conclusions: Susac syndrome is a disease that requires a high clinical suspicion, especially in pregnant women. Treatment in pregnancy or puerperium is not well established. Précis: Susac syndrome is a disease that requires a high clinical suspicion, especially in pregnant women. Treatment in pregnancy or puerperium is not well established.
Collapse
Affiliation(s)
- Luis Ramos-Ruperto
- Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain
| | | | | | | |
Collapse
|
8
|
Cognitive dysfunction and brain atrophy in Susac syndrome. J Neurol 2019; 267:994-1003. [DOI: 10.1007/s00415-019-09664-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 11/30/2019] [Accepted: 12/03/2019] [Indexed: 10/25/2022]
|
9
|
Heng LZ, Bailey C, Lee R, Dick A, Ross A. A review and update on the ophthalmic implications of Susac syndrome. Surv Ophthalmol 2019; 64:477-485. [DOI: 10.1016/j.survophthal.2019.01.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 01/10/2019] [Accepted: 01/17/2019] [Indexed: 11/26/2022]
|